Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

References

• Kaspers G J, Zwaan C M. Pediatric acute myeloid leukemia: towards high-.quality cure of all patients. Haematologica 2007; 92: 1519–1532
   PubMed Web of Science ®Google Scholar
• Ravindranath Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Cur Opin Oncol 2003; 15: 23–35
   PubMed Web of Science ®Google Scholar
• Ter Bals E, Kaspers G J. Treatment of childhood acute myeloid leukemia. Expert Rev Anticancer Ther 2005; 5: 917–929
   PubMed Web of Science ®Google Scholar
• Howard S C, Marioni M, Castillo L, et al. Improving outcomes for children with cancer in low income countries in Latin America: a report on the recent meeting of the Monza International School of Pediatric Hematology/Oncology (MISPHO) Part I. Ped Blood Can 2007; 48: 364–369
   PubMed Web of Science ®Google Scholar
• Yeh T C, Liu H C, Wang L Y, Chen S H, Lin W Y, Liang D C. The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J Pediatr Hematol Oncol 2007; 29: 826–831
   PubMed Web of Science ®Google Scholar
• Tan R M, Quah T C, Aung L, Liang S, Kirk R C, Yeoh A E. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol. Pediatr Blood Cancer 2007; 48: 262–267
   PubMed Web of Science ®Google Scholar
• Liang D C, Chan T T, Lin K H, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006; 20: 136–141
   PubMed Web of Science ®Google Scholar
• Stevens R F, Hann I M, Wheatley K, Gray R G. on behalf of the MRC Childhood Leukaemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998; 101: 130–140
   PubMed Web of Science ®Google Scholar
• Zwaan G M, Kaspers G J, Pieters R, et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002; 100: 3352–3360
   PubMed Web of Science ®Google Scholar
• Creutzig U, Ritter J, Riehm H, et al. Improved treatment results in childhood acute myelogenous leukemia: a report of the German Cooperative Study AML-BFM-78. Blood 1985; 65: 298–304
   PubMed Web of Science ®Google Scholar
• Kaspers G JL, Creutzig U. Pediatric acute myeloid leukemia: internacional progress and future directions. Leukemia 2005; 19: 2025–2029
   PubMed Web of Science ®Google Scholar
• Steuber C P, Civin C, Krischer J, et al. A comparison of induction and maintenance therapy for acute nonloymphocytic leukemia in childhood: results of a Pediatric Oncology Group study. J Clin Oncol 1991; 9: 247–258
   PubMed Web of Science ®Google Scholar
• Weinstein H J, Mayer R J, Rosenthal D S, et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315–319
   PubMed Web of Science ®Google Scholar
• Entz-Werle N, Suciu S, Jvan der Werff ten Bosch J, et al. Results of 58,872 and 58,921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs. allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005; 19: 2072–2081
   PubMed Web of Science ®Google Scholar
• Kardos G, Zwaan C M, Kaspers G JL, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 2005; 19: 2063–2071
   PubMed Web of Science ®Google Scholar
• Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2005; 2117–2124
   PubMed Web of Science ®Google Scholar
• Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloıde Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 4377–4785
   PubMed Web of Science ®Google Scholar
• Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005; 19: 2043–2053
   PubMed Web of Science ®Google Scholar
• Creutzig U, Reinhardt D, Zimmermann M, Klingebiel T, Gadner H. Intensive chemotherapy vs. BMT in pediatric AML – a matter of controversies. Blood 2001; 97: 3671–3672
   PubMed Web of Science ®Google Scholar
• Alonzo T A, Wells R J, Woods W G, et al. Postremission therapy for children with acute myeloid leukemia: the Children's cancer group experience in the transplant era. Leukemia 2005; 19: 965–970
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Chang M, Steuber C P, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101–2116
   PubMed Web of Science ®Google Scholar
• Perel Y, Auvrignon A, Leblanc T, et al. Maintenance therapy in childhood acute myeloid leukemia. Ann Hematol 2004; 83: S116–S119
   PubMedGoogle Scholar
• Perel1 Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leuce'mie Aigue¨ Myeloblastique Enfant) Cooperative Group. Leukemia 2005; 19: 2082–2089
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmerman M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042
   PubMed Web of Science ®Google Scholar
• Gibson B ES, Wheatley K, Hann I M, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130–2138
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt M, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393
   PubMed Web of Science ®Google Scholar
• Rubnitz J, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude Experience. Cancer 2004; 101: 1677–1684
   PubMed Web of Science ®Google Scholar
• Slats A M, Egeler R M, Does-van den Berg A, et al. Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005; 19: 537–544
   PubMed Web of Science ®Google Scholar
• Viana M B, Cunha K C, Ramos G, Murao M. Acute myeloid leukemia in childhood: fifteen-year experience in a single institution. J Pediatr (Rio) 2003; 79: 489–496
   PubMedGoogle Scholar
• Armendariz H, Barbieri M A, Freigeiro D, Lastiri F, Felice M S, Dibar E. Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials. Leukemia 2005; 19: 2139–2142
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel W E, Schoch M, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480–2489
   PubMed Web of Science ®Google Scholar